Voyager Therapeutics, Inc. (VYGR) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Agenus, Inc.

Precigen, Inc.

Voyager Therapeutics, Inc.

Scholar Rock Holding Corp.

Edgewise Therapeutics, Inc.

Mineralys Therapeutics, Inc.

Aerovate Therapeutics, Inc.

iTeos Therapeutics, Inc.

Nautilus Biotechnology, Inc.

Lyell Immunopharma, Inc.

Aldeyra Therapeutics, Inc.

Why is Voyager Therapeutics, Inc. ?

Negative results in Jun 26

OPERATING CASH FLOW(Y) Lowest at USD -120.57 MM
NET SALES(Q) At USD 3.17 MM has Fallen at -65.31%
ROCE(HY) Lowest at -54.09%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 1.55%, its profits have fallen by -84.2%

Underperformed the market in the last 1 year

The stock has generated a return of 1.55% in the last 1 year, much lower than market (S&P 500) returns of 22.36%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Voyager Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Voyager Therapeutics, Inc.

1.55%

-1.00

62.91%

S&P 500

22.36%

1.69

13.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-25.09%

EBIT Growth (5y)

-236.94%

EBIT to Interest (avg)

-10.21

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.84

Sales to Capital Employed (avg)

0.42

Tax Ratio

0.82%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

65.74%

ROCE (avg)

ROE (avg)

14.16%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.20

EV to EBIT

-0.36

EV to EBITDA

-0.37

EV to Capital Employed

6.34

EV to Sales

1.17

PEG Ratio

Dividend Yield

ROCE (Latest)

-1764.04%

ROE (Latest)

-61.06%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

OPERATING PROFIT(Q)

Highest at USD -25.48 MM

PRE-TAX PROFIT(Q)

Highest at USD -24.45 MM

NET PROFIT(Q)

Highest at USD -24.47 MM

EPS(Q)

Highest at USD -0.4

-15What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -120.57 MM

NET SALES(Q)

At USD 3.17 MM has Fallen at -65.31%

ROCE(HY)

Lowest at -54.09%

RAW MATERIAL COST(Y)

Grown by 10.46% (YoY

CASH AND EQV(HY)

Lowest at USD 257.82 MM

DEBT-EQUITY RATIO (HY)

Highest at -54.26 %

Here's what is working for Voyager Therapeutics, Inc.

Operating Profit

Highest at USD -25.48 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit

Highest at USD -24.45 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD -24.47 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD -0.4

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Here's what is not working for Voyager Therapeutics, Inc.

Net Sales

At USD 3.17 MM has Fallen at -65.31%

over average net sales of the previous four periods of USD 9.12 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Operating Cash Flow

Lowest at USD -120.57 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Cash and Eqv

Lowest at USD 257.82 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -54.26 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 10.46% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales